INVESTIGATIVE REPORT

Cytokine Profile of Patients with Mycosis Fungoides and the Immunomodulatory Effect of AS101

M. SHOHAT¹, E. HODAK¹, B. SREDNI², B. SHOHAT², D. SREDNI² and M. DAVID¹

Departments of ¹Dermatology and ²Cellular Immunology Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ³C.A.I.R. Institute, Bar Ilan University, Ramat Gan, Israel

Cytokines are known to play a major role in the pathogenesis of mycosis fungoides, a cutaneous malignant neoplasm of CD 4 T cells. In the present study, we investigated the effect of AS101, a tellurium-based compound with immunomodulating properties, on the pattern of lymphokine production by peripheral blood mononuclear cells (PBMCs) from patients with mycosis fungoides. PBMCs were isolated from 35 patients with mycosis fungoides stage IA and IB before initiation of treatment and from 20 healthy sex and age-matched controls. Unstimulated and phytohaemagglutinin-stimulated PBMCs were tested with and without the addition of AS101. The production of interferon-γ, interleukin 2 (IL-2), IL-2 receptor (IL-2R), interleukin 5 (IL-5) and interleukin 10 (IL-10) was determined by enzyme-linked immunosorbent assays. The effects of AS101 on mycosis fungoides PBMCs were compared to those of healthy donor PBMCs. Significantly higher levels of IL-2R, IL-5 and IL-10 and significantly lower levels of interferon-γ were found in the patients compared to the controls. There was no significant difference between the groups in the production of IL-2. AS101 inhibited the production of IL-2R, IL-5 and IL-10 and induced a significant increase in IL-2 levels in the mycosis fungoides PBMCs. These findings may have important clinical implications for the possible therapeutic benefit of AS101 in mycosis fungoides. Key words: mycosis fungoides; immunomodulation; T-helper 2 profile; T-helper 1 profile; AS101.

(Accepted May 16, 2001.)

Acta Derm Venereol 2001; 81: 255–257.

M. Shohat, MD, Department of Dermatology, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel. E-mail: mdavid@eliot.org.il

Mycosis fungoides (MF) is a lymphoproliferative disorder characterized by infiltration of the skin with clone-derived malignant CD4+ lymphocytes which phenotypically resemble mature T helper (Th) cells (1–3). Cytokines are considered to play a major role in the pathogenesis of MF (2, 4, 5). The skin manifestations are divided into clinicopathologic stages of increasing aggression: patch, plaque and tumour (4, 6, 7). Saed et al. (8) reported that the cutaneous lesions of plaque stage MF are characterized by an epidermal Th1-type cytokine profile, whereas Vowels et al. (5) detected a Th2 cytokine profile in some plaque biopsies and in all tumour-stage biopsies. MF progression has been associated with increasing cutaneous overexpression of IL-10 mRNA (9).

AS101, a tellurium-based compound with known immunomodulating properties, has been shown to inhibit the release of IL-10 by lipopolysaccharide-stimulated mouse peritoneal macrophages and human monocytes and to block the transcription of IL-10 mRNA (10). It also enhances the production of interleukin-2 (IL-2), tumour necrosis factor and interferon-gamma (IFN-γ) by human mononuclear cells (11–15). The effects of AS101 on interleukin 5 (IL-5) production in general and on peripheral blood mononuclear cells (PBMC) in MF have not been studied previously.

In the present study, we investigated the cytokine profile of resting and activated PBMC in patients with MF and the effect of AS-101 on this profile compared with healthy donor PBMCs.

MATERIALS AND METHODS

Subjects

The study population, comprising 35 patients (25 males and 10 females) aged between 40 and 75 years, were diagnosed based on clinical, histopathological and immunohistologic criteria (16). All patients were in either stage IA or IB before initiation of treatment and had no atopic diseases. Twenty healthy age- and sex-matched subjects served as the control group.

Methods

AS-101 was prepared by diluting a sterile solution of this compound, which was supplied by Wyeth-Ayerst, Randall, PA, and licensed by IVAX, Miami, FL, USA. Blood samples were drawn from all participants, and PBMCs were isolated on Ficoll-Paque gradients and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 µg/ml penicillin and 100 µg/ml streptomycin. The cells were incubated in 24-well flat-bottomed culture plates at 37°C in a humidified atmosphere with 5% CO₂ for 48 h. Phytohaemagglutinin (PHA) (Ta’asit Biologist, Bei Haemek, Israel) 0.5% was used as a stimus. Supernatants were harvested at 48 h and stored at −70°C until tested. IL-10, IFN-γ, IL-2, IL-2 receptor (IL-2R) and IL-5 were measured with enzyme-linked immunosorbent assay (ELISA) kits (Endogen, Inc., Woburn, MA, USA) in accordance with the manufacturer’s instructions. All samples were run in duplicate. AS101 was added at a concentration of 0.5 µg/ml, as this concentration was found to yield optimal effects. Statistical analysis was performed with Student’s t-test. The results are presented as means ± SD. The detection limits for IL-10 were 3 pg/ml for IFN-γ, 2 pg/ml for IL-2, 6 pg/ml for IL-2R 24 u/ml and 2 pg/ml for IL-5.

RESULTS

The mean levels and SD of IL-10, IFN-γ, IL-2, IL-2R and IL-5 production by PBMC obtained from the MF patients and healthy controls are shown in Fig. 1A–E. As no significant difference in cytokine release was noted between the PBMC obtained from the MF patients, stage IA and IB, we analysed all the patients as a single group.

For IL-2, IL-2R and IL-5, the effect of AS101 was tested only on PHA-stimulated PBMCs, as unstimulated PBMCs showed undetectable levels of these cytokines. The levels of
IL-10 and IFN-γ were detectable in both stimulated and unstimulated PBMCs of MF patients.

IL-10 production was significantly higher in both unstimulated and PHA-stimulated PBMCs from the patients with MF ($p < 0.05$), and was significantly decreased by AS101 from a mean of 6.89 ± 3.24 ng/ml in PHA-stimulated PBMC to only 0.52 ± 0.14 ng/ml ($p < 0.01$) (Fig. 1A), and from a level of 0.70 ± 0.361 in unstimulated PBMCs of MF to a level of only 0.09 ± 0.004 ($p < 0.01$).

IFN-γ production was significantly lower in PHA-stimulated PBMCs from patients with MF (mean 1099 ± 552 pg/ml) compared to controls (mean 2032 ± 860 pg/ml) ($p < 0.05$). AS101 significantly increased the spontaneous release of IFN-γ by unstimulated PBMCs of patients with MF ($p < 0.05$), but not of PHA-stimulated PBMCs (Fig. 1B). IL-2 production by PHA-stimulated PBMCs was similar in the two groups, but the addition of AS101 induced a fourfold increase in the MF PBMCs, from a mean of 72 ± 34 pg/ml to 288 ± 109 pg/ml (Fig. 1C). This difference was highly significant ($p < 0.003$). No significant difference was found in the control group after addition of AS-101. Soluble IL-2R and IL-5 production by the PHA-stimulated PBMCs was higher compared to controls ($p < 0.05$ and $p < 0.01$, respectively). AS101 significantly inhibited the IL-2R and IL-5 release by the MF PBMCs ($p < 0.01$ and $p < 0.03$, respectively) (Fig. 1D, E), but had no effect on IL-5 of the healthy control cells (Fig. 1E). The cytokine values were normally distributed in each single group of both MF patients and controls.

DISCUSSION

The progression of MF has been found to be associated with increasing overexpression of mRNA IL-10 in cutaneous lesions (9). As IL-10 suppresses the production of IFN-γ, it may be assumed that the stage-dependent decrease in IFN-γ mRNA expression observed in tumour stage MF compared to the
patch and plaque stage (5, 9) may be the result of IL-10 enhancement. Previous studies have shown that the transcription of IL-10 mRNA can be blocked by AS101 (8, 10). Saed et al. have tested the blood cytokine mRNA levels in patients with MF and reported no difference in cytokine pattern between MF and healthy controls (8). However, our study differs from theirs in that we tested the production of five different cytokines by PHA-stimulated PBMCs. We found a significantly lower release of IFN-γ and a significantly higher production of IL-10, IL-5 and IL-2R, while no difference was found in the IL-2 production in PHA-stimulated PBMC from patients with MF compared to controls. The decrease shown in IFN-γ is in agreement with the findings of Lee et al. (17) and of Vowels et al. (5) in stimulated MF and Sézary cells; however, they did not test IL-10 production.

We did not find any defect in the ability of PBMCs of patients with MF to synthesize IL-2. In a study by Rook et al. (18), the poor IL-12 production by PBMCs from patients with Sézary syndrome increased five- to sixfold with the addition of neutralizing monoclonal anti-IL-10 antibodies. These authors also detected a significant increase in IFN-γ production by the Sézary syndrome PBMCs when the IL-10 was neutralized (18). Our finding of a more than twofold increase in soluble IL-2R release by stimulated PBMCs of MF patients compared to controls is in accordance with that of Wasik et al. (19), who showed an increased serum concentration of soluble IL-2R in cutaneous T-cell lymphoma.

The different effects of AS101 on PBMCs from patients with MF and normal healthy controls can be explained by its immunomodulator properties, which enable it to act in opposite ways (10).

We conclude that there is a Th2-type cytokine production in MF stage IA and IB PBMCs in response to PHA stimulation similar to that found in Sézary syndrome. AS101, by inhibiting IL-10 production, may induce an increase in IFN-γ production and a shift from Th2 to a Th1-type cytokine profile. This finding has important implications for the possible therapeutic role of AS101 in MF.

ACKNOWLEDGEMENTS

We thank Mrs. Charlotte Sachs and Mrs. Gloria Ginzach of the Editorial Board, Rabin Medical Center, Beilinson Campus, for their assistance. This work was performed as a partial requirement for the PhD thesis of M. Shohat, MD.

REFERENCES

1. Edelson RL. Cutaneous T-cell lymphoma: mycosis fungoides, Sézary syndrome and other variants. J Am Acad Dermatol 1980; 2: 89–106.
2. Haynes BF, Bunn P, Mann D, Thomas C. Cell differentiation antigens of the malignant T cell in Sézary syndrome and mycosis fungoides. J Clin Invest 1981; 67: 523–528.
3. Weiss L, Hu E, Wood G, Moulds C, Cleary ML, Sklar J. Clonal rearrangement of T-cell receptor in mycosis fungoides and dermatopathic lymphadenopathy. J Med 1985; 313: 539–544.
4. Burg G, Haffner A, Boni R, Dommann S, Dummer R. New perspectives in experimental and clinical research for cutaneous T-cell lymphomas. Recent Results Cancer Res 1993; 139: 225–230.
5. Vowels BR, Cassin M, Vanderheid EC, Rook AH. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90–94.
6. Hsu SM, Waldron JW, Hsu PL, Hough AJ. Cytokines in malignant lymphoma: review and prospective evaluation. Hum Pathol 1993; 24: 1040–1046.
7. Rook AH, Kulbin M, Cassin M, Vanderheid EC, Vowels BR, Wolfe JT, et al. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1990; 154: 1491–1495.
8. Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sézary syndrome expresses a Th2 type profile. J Invest Dermatol 1994; 103: 29–33.
9. Asadullah K, Docke WD, Haeussler A, Sterry W, Volkhaus-Dieter, et al. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996; 107: 833.
10. Strassman G, Kamboyashi T, Lacob CO, Sredni D. The immunomodulator AS-101 inhibits IL-10 release and augments TNF-α and IL-1β release by mouse and human mononuclear phagocytes. Cell Immunol 1997; 176: 180–185.
11. Sredni B, Kalechman Y, Albeck M, Gross O, Aurbach D, Sharon P, et al. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase-C inducer bryostatin. Immunology 1990; 70: 473–477.
12. Kozenitsky L, David M, Sredni B, Albeck M, Shohat B. Immunomodulatory effects of AS101 on interleukin-2 production and T-lymphocyte function of lymphocytes treated with psoralsens and ultraviolet A. Photodermat Photoimmun Photomed 1992; 9: 24–28.
13. Shohat B, Kozenitzki L, David M, Albeck M, Sredni B. Effect of UVB and AS101 on interleukin-2 production and helper activity in psoriatic patients. Natl Immunol 1993; 12: 50–55.
14. Sredni B, Kalechman Y, Shalit F, Albeck M. Synergism between AS101 and PMA in lymphokine production. Immunology 1990; 69: 110–116.
15. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Shegal SN, et al. The radioprotective effects of the immunomodulator AS101. J Immunol 1990; 145: 1512–1517.
16. Murphy GF. Cutaneous T cell lymphoma. Adv Pathol 1988; 1:131–156.
17. Lee BN, Duvic M, Tang CW, Bueso-Ramо C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6: 79–84.
18. Rook A, Kubin M, Fox F, Niu Z, Cassin M, Vowels BR, et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann NY Acad Sci 1996; 795: 310.
19. Wasik MA, Vanderheid EC, Bigler RD, Masti R, Lessen SR, Polansky M, et al. Increased serum concentration of soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Arch Dermatol 1996; 132: 42–47.